Abstract
Prostate cancer is currently the most prevalent cancer among men in the United States and ranks second to lung cancer in terms of annual mortality. The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to the therapeutic response to hormones. Although it has been known for many years that the expression and activity of AR is controlled by AR coregulators, the manipulation of endogenous AR coregulators to affect AR levels or function has not been widely exploited clinically. Coregulators are proteins that interact with AR to either enhance (coactivators) or reduce (corepressors) transcriptional activity. They act via a variety of mechanisms that provide potential therapeutic targets. The purpose of this article is to review the evidence for the deregulated expression and activity of AR associated coregulators in the progression of prostate cancer. The therapeutic use of these coregulators in both clinical and preclinical models is discussed with the aim of suggesting new modalities for prostate cancer treatment.
Keywords: Prostate cancer, androgen receptor, AR coactivators, AR corepressors
Current Cancer Therapy Reviews
Title: New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators
Volume: 6 Issue: 3
Author(s): Yuexing Zhang and Anne W. Hamburger
Affiliation:
Keywords: Prostate cancer, androgen receptor, AR coactivators, AR corepressors
Abstract: Prostate cancer is currently the most prevalent cancer among men in the United States and ranks second to lung cancer in terms of annual mortality. The androgen receptor (AR) is central to the initiation and growth of prostate cancer and to the therapeutic response to hormones. Although it has been known for many years that the expression and activity of AR is controlled by AR coregulators, the manipulation of endogenous AR coregulators to affect AR levels or function has not been widely exploited clinically. Coregulators are proteins that interact with AR to either enhance (coactivators) or reduce (corepressors) transcriptional activity. They act via a variety of mechanisms that provide potential therapeutic targets. The purpose of this article is to review the evidence for the deregulated expression and activity of AR associated coregulators in the progression of prostate cancer. The therapeutic use of these coregulators in both clinical and preclinical models is discussed with the aim of suggesting new modalities for prostate cancer treatment.
Export Options
About this article
Cite this article as:
Zhang Yuexing and W. Hamburger Anne, New Therapies for Prostate Cancer Based on the Biology of Androgen Receptor Coregulators, Current Cancer Therapy Reviews 2010; 6 (3) . https://dx.doi.org/10.2174/157339410791698205
DOI https://dx.doi.org/10.2174/157339410791698205 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Signatures of Biomarkers in Cancer Development, Diagn osis, and its Prognostic Accuracy
Current Biomarkers (Discontinued) Metabotropic Glutamate Receptor 5 in Down's Syndrome Hippocampus During Development: Increased Expression in Astrocytes
Current Alzheimer Research Targeting the Tumor Stroma with Peroxisome Proliferator Activated Receptor (PPAR) Agonists
Anti-Cancer Agents in Medicinal Chemistry Insulin Secretagogues, Sulfonylurea Receptors and KATP Channels
Current Pharmaceutical Design Inhibition of Pyruvate Dehydrogenase Kinase as a Therapeutic Strategy against Cancer
Current Topics in Medicinal Chemistry 4-Oxothiazolidines with Exocyclic C=C Double Bond(s): Synthesis, Structure, Reactions and Biological Activity
Current Organic Chemistry Hybrid Molecules Development: A Versatile Landscape for the Control of Antifungal Drug Resistance: A Review
Mini-Reviews in Medicinal Chemistry Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications
Current Medicinal Chemistry Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Cellular FLICE-Like Inhibitory Protein (C-FLIP): A Novel Target for Cancer Therapy
Current Cancer Drug Targets Intracellular Delivery of Potential Therapeutic Genes: Prospects in Cancer Gene Therapy
Current Gene Therapy Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Current Developments on Synthesis, Redox Reactions and Biochemical Studies of Selenium Antioxidants
Current Chemical Biology Therapeutic Perspectives on Pancreatic Cancer
Current Cancer Drug Targets Radiation-Induced Pulmonary Epithelial-Mesenchymal Transition: A Review on Targeting Molecular Pathways and Mediators
Current Drug Targets Recent Advances of Natural and Synthetic β-Carbolines as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Overview of the Metallometabolomic Methodology for Metal-Based Drug Metabolism
Current Drug Metabolism Evaluation of Antioxidant Capacity and Phenolic Content in Ethanolic Extracts of Leaves and Flowers of Some Asteraceae Species
Recent Patents on Food, Nutrition & Agriculture Cancer Gene Therapy Utilizing Interleukin-13 Receptor α2 Chain
Current Gene Therapy Diabetes Gene Therapy: Potential and Challenges
Current Gene Therapy